A Glimpse into the Scary World of Vaccine Adjuvants

Otherhealth.com 

Posted by Sherri Naken
November 19, 2008

UK – New AS04 adjuvant (in Cervarix & others) – EddaWest/VRAN, Canada

EXCERPT…………………

So what exactly is this new high potency adjuvant? We’re told by the
press release that MPL (AS04), is a “derivative of the lipid A
molecule found in Gram-negative bacteria, is extracted from bacterial
cell walls and is one of the most potent regulators of the immune
response, used by the body to alert itself to bacterial
infections.”(12) Full name of the lipid is monophosphoryl lipid A (MPL)

This news should put everyone on high alert because guess
what? Lipids are oils/fatty acids and according to Matsumoto, MPL is
identified in declassified documents as one of two squalene emulsions
used in the Army’s new “recombinant protective antigen anthrax
vaccine (rPA) which the FDA, the National Institutes of Health (NIH)
and the Department of Defense fast-tracked into clinical trials
in1998. The other squalene adjuvant they used was Chiron’s MF59. (6)

It appears that Fendrix is only the first of a whole new generation
of “enhanced potency” vaccines coming down the pipeline using the new
high potency lipid adjuvant, MPL. “The adjuvant is also being used
in a number of GSK’s developmental vaccines, including one that could
be the first effective vaccine for malaria”, says the article. MPL
(AS04) adjuvant is also a component of GSK Bio’s genital herpes
vaccine, as well as a component in their cervical cancer vaccine and
a new tuberculosis vaccine.” (12)

In the unraveling of the squalene story, we find that a squalene
emulsion first known as Triple Mix (based on Freund’s adjuvant) was
later given the commercial name “Ribi”. Triple Mix (renamed Ribi)
was tested by Dutch scientists on rabbits who found it caused “severe
effects.the largest number and most severe lesions when compared with
the other adjuvants.”(6) Then in June 1999, Ribi ImmunoChem its
manufacturer was acquired by Corixa Corporation for $56.3 million,
who presumably also own the Ribi formulation. Whether MPL(AS04) is a
formula related to Ribi is undoubtedly “proprietary” information, but
from Matsumoto’s reseasrch, we know they are all squalene based. And
it doesn’t end there. MPL, Corixa’s multi-million dollar baby, is
slated for inclusion not only in the “enhanced potency” vaccines
already mentioned, but will also be a strategic component of new
allergy and autoimmune vaccines in development. (13)

From their inception, mass vaccinations have acted as a biological
weapon, undermining health, manipulating and crippling the immune
system, and instigating cycles of new and debilitating
diseases. Monopoly medicine’s solution? Inject us with more
powerful, genetically engineered high potency vaccines. Never mind
they are seeding us with “nano-bombs” that will further attack our
already compromised immune systems.

MORE…

PG

Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.